Insights & Resources

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.

The instances of urgent care clinic visits have returned to pre-pandemic levels, but COVID-related services still make up a large percentage of the total volume.

The home health and hospice sectors are facing significant challenges with personal care emerging as the key sector for mitigating risk.

High-growth specialties are influencing the fair market value of ambulatory surgery centers and setting new standards for premium valuations.

Explore Weaver's insights on the current health care deal volume decline and valuation.

Recent trends in financial performance & provider productivity show challenges facing medical groups related to practice margins. What does it mean for valuations?

In any health care segment, buyer concentration can have an effect on valuation pricing and is one of the key macro-dynamics that should be considered in a health care valuation analysis.

Get ahead of the curve by looking back at emerging trends in 2023 that are likely to impact health care valuation in 2024 and beyond. Download Weaver Insights now.

Changing Medicare populations, staffing shortages and other issues create challenges for valuations of home health care agencies.